Ipca Laboratories has informed that pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, they had vide letter dated 5th December, 2025, intimated about US FDA inspection of Company’s Active Pharmaceutical Ingredients (API) manufacturing facility situated at Tarapur (Palghar-Maharashtra) from 1st December, 2025 to 5th December, 2025. This manufacturing facility has now received Establishment Inspection Report classifying the manufacturing facility as Voluntary Action Indicated (VAI) and that this facility is considered to be in a minimally acceptable state of compliance with regard to current good manufacturing practice (CGMP).
The above information is a part of company’s filings submitted to BSE.
